Quarterly report · Q1
4587.TEDINET S100TFRV
Period2024-01-01 → 2024-03-31
Filed2024-05-15
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 48
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥4.2bn | 2024-01-01 → 2024-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥28.7bn | 2023-01-01 → 2023-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥5.0bn | 2023-01-01 → 2023-03-31 | Cons. | Revenue IFRS |
| Operating income | −¥1.1bn | 2024-01-01 → 2024-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | −¥267m | 2023-01-01 → 2023-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | −¥1.1bn | 2024-01-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥4.4bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | −¥400m | 2023-01-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | −¥843m | 2024-01-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥3.0bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | −¥249m | 2023-01-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | −¥843m | 2024-01-01 → 2024-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥3.0bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss IFRS (5-year summary) |
| Net income | −¥249m | 2023-01-01 → 2023-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥69.6bn | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥69.5bn | at 2023-12-31 | Cons. | Assets IFRS |
| Total assets | ¥59.8bn | at 2023-03-31 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥29.7bn | at 2024-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥29.1bn | at 2023-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥40.0bn | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥40.3bn | at 2023-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥31.8bn | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥32.0bn | at 2022-12-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥40.0bn | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥40.3bn | at 2023-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥31.8bn | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥27.3bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥19.5bn | at 2023-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥11.6bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥5.2bn | at 2022-12-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | −¥1.9bn | 2024-01-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥12.4bn | 2023-01-01 → 2023-12-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥7.7bn | 2023-01-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | ¥10.4bn | 2024-01-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | ¥1.3bn | 2023-01-01 → 2023-12-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥381m | 2023-01-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥757m | 2024-01-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥264m | 2023-01-01 → 2023-12-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥1.1bn | 2023-01-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥-6.5 | 2024-01-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥23.41 | 2023-01-01 → 2023-12-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥-1.92 | 2023-01-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥-6.5 | 2024-01-01 → 2024-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥23.38 | 2023-01-01 → 2023-12-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥-1.92 | 2023-01-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 57.4% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 58.1% | at 2023-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 53.2% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 26
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-01-01 → 2024-03-31 | −¥75m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-01-01 → 2024-03-31 | −¥75m |
| jpcrp040300-q1r_E27486-000Drug Discovery And Development Businessreportable segment | revenue | 2024-01-01 → 2024-03-31 | ¥521m |
| jpcrp040300-q1r_E27486-000Drug Discovery And Development Businessreportable segment | revenue external | 2024-01-01 → 2024-03-31 | ¥521m |
| jpcrp040300-q1r_E27486-000Drug Discovery And Development Businessreportable segment | segment profit | 2024-01-01 → 2024-03-31 | −¥955m |
| jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segment | revenue | 2024-01-01 → 2024-03-31 | ¥3.8bn |
| jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segment | revenue external | 2024-01-01 → 2024-03-31 | ¥3.7bn |
| jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segment | revenue intersegment | 2024-01-01 → 2024-03-31 | ¥75m |
| jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segment | segment profit | 2024-01-01 → 2024-03-31 | −¥121m |
| —segment total | revenue | 2024-01-01 → 2024-03-31 | ¥4.3bn |
| —segment total | revenue external | 2024-01-01 → 2024-03-31 | ¥4.2bn |
| —segment total | revenue intersegment | 2024-01-01 → 2024-03-31 | ¥75m |
| —segment total | segment profit | 2024-01-01 → 2024-03-31 | −¥1.1bn |
| Reconciling Itemsreconciling | revenue | 2023-01-01 → 2023-03-31 | −¥3m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-01-01 → 2023-03-31 | −¥3m |
| jpcrp040300-q1r_E27486-000Drug Discovery And Development Businessreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥978m |
| jpcrp040300-q1r_E27486-000Drug Discovery And Development Businessreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥978m |
| jpcrp040300-q1r_E27486-000Drug Discovery And Development Businessreportable segment | segment profit | 2023-01-01 → 2023-03-31 | −¥381m |
| jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥4.0bn |
| jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥4.0bn |
| jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segment | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥3m |
| jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segment | segment profit | 2023-01-01 → 2023-03-31 | ¥136m |
| —segment total | revenue | 2023-01-01 → 2023-03-31 | ¥5.0bn |
| —segment total | revenue external | 2023-01-01 → 2023-03-31 | ¥5.0bn |
| —segment total | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥3m |
| —segment total | segment profit | 2023-01-01 → 2023-03-31 | −¥244m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 513
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 130010400 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 130010400 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 130010400 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 130010400 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 200 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 1299749 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 129974900 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | 35300 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant | 130010400 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant | 1299749 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant_Row1Member | 200 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant_Row1Member | 200 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant_Row1Member | 0.0000 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant | 200 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant | 200 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant | 0.0000 | |
| Cash and cash equivalents IFRS | Prior1YearInstant | 19507861000 | JPY |
| Cash and cash equivalents IFRS | CurrentQuarterInstant | 27335184000 | JPY |
| Trade and other receivables ca IFRS | Prior1YearInstant | 4970860000 | JPY |
| Trade and other receivables ca IFRS | CurrentQuarterInstant | 4728579000 | JPY |
| Other financial assets ca IFRS | Prior1YearInstant | 6245000 | JPY |
| Other financial assets ca IFRS | CurrentQuarterInstant | 6245000 | JPY |
| Inventories ca IFRS | Prior1YearInstant | 2404156000 | JPY |
| Inventories ca IFRS | CurrentQuarterInstant | 2738378000 | JPY |
| Other current assets ca IFRS | Prior1YearInstant | 335959000 | JPY |
| Other current assets ca IFRS | CurrentQuarterInstant | 563234000 | JPY |
| Current assets IFRS | Prior1YearInstant | 27225082000 | JPY |
| Current assets IFRS | CurrentQuarterInstant | 35371622000 | JPY |
| Property plant and equipment IFRS | Prior1YearInstant | 17358317000 | JPY |
| Property plant and equipment IFRS | CurrentQuarterInstant | 17451260000 | JPY |
| Goodwill IFRS | Prior1YearInstant | 8370677000 | JPY |
| Goodwill IFRS | CurrentQuarterInstant | 8370677000 | JPY |
| Intangible assets IFRS | Prior1YearInstant | 2211452000 | JPY |
| Intangible assets IFRS | CurrentQuarterInstant | 2177681000 | JPY |
| Investments accounted for using equity method IFRS | Prior1YearInstant | 81067000 | JPY |
| Investments accounted for using equity method IFRS | CurrentQuarterInstant | 2934000 | JPY |
| Other financial assets nca IFRS | Prior1YearInstant | 11801205000 | JPY |
| Other financial assets nca IFRS | CurrentQuarterInstant | 1528815000 | JPY |
| Deferred tax assets IFRS | Prior1YearInstant | 2337218000 | JPY |
| Deferred tax assets IFRS | CurrentQuarterInstant | 4653496000 | JPY |
| Retirement benefit asset nca IFRS | Prior1YearInstant | 32146000 | JPY |
| Retirement benefit asset nca IFRS | CurrentQuarterInstant | 34660000 | JPY |
| Other non current assets nca IFRS | Prior1YearInstant | 46845000 | JPY |
| Other non current assets nca IFRS | CurrentQuarterInstant | 45994000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |